Mild illness at or after measles vaccination does not reduce seroresponse in young children.

We analyzed data from a randomized trial of AIK-C, high-titre (EZ-H) or medium-titre EZ (EZ-M) vaccines in 3.5 and 6 month old infants in Kinshasa, Zaire, in which the occurrence of rhinorrhoea, cough, diarrhoea, fever, conjunctivitis or rash was monitored for 15 days post-vaccination (including the day of vaccination, day 0). We compared sero-response at 6 weeks and 6 months post-vaccination among children with and without mild illness at or after vaccination.

Immunogenicity of high-titre AIK-C or Edmonston-Zagreb vaccines in 3.5-month-old infants, and of medium- or high-titre Edmonston-Zagreb vaccine in 6-month-old infants, in Kinshasa, Zaire.

The effect of measles vaccine potency was evaluated among 485 children aged 6 months, and the effect of vaccine strain was evaluated among 538 children aged 3.5 months, in Kinshasa, Zaire. Children aged 6 months were randomly assigned to receive either high-titre Edmonston-Zagreb (EZ-H), potency 5.

Measles control in Kinshasa, Zaire improved with high coverage and use of medium titre Edmonston Zagreb vaccine at age 6 months.

Background: To improve measles control in Kinshasa, Zaire, a project to increase vaccine coverage was begun in 1988, and in 1989, the city vaccination programme changed measles vaccination policy from Schwartz vaccine at age 9 months to medium titre Edmonston Zagreb (EZ) vaccine at age 6 months. We report the impact of the programme on measles incidence and mortality.

Methods: Data on vaccine coverage were obtained from cluster sample surveys conducted every 1-2 years and from routine reports of vaccine doses administered.